United States-Israel Alzheimer's Disease Cooperation Act - Directs the Secretary of Health and Human Services (HHS) to establish a program of grants to support research on the development and commercialization of tools, treatments, and cures for Alzheimer's disease and other dementias.
Requires eligible projects to be joint ventures between U.S. and Israeli non-governmental entities or the U.S. and Israeli governments.
Establishes an advisory board to monitor the method by which grants are awarded and to provide performance reviews of actions taken to carry out this Act.
[Congressional Bills 113th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4798 Introduced in House (IH)]
113th CONGRESS
2d Session
H. R. 4798
To authorize the Secretary of Health and Human Services to award grants
for Alzheimer's disease research.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 2, 2014
Mr. Israel introduced the following bill; which was referred to the
Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To authorize the Secretary of Health and Human Services to award grants
for Alzheimer's disease research.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``United States-Israel Alzheimer's
Disease Cooperation Act''.
SEC. 2. FINDINGS.
The Congress finds the following:
(1) It is in the highest national interests of the United
States to further research into Alzheimer's disease.
(2) The State of Israel is a steadfast ally of the United
States.
(3) The special relationship between the United States and
Israel is manifested in a variety of cooperative scientific
research and development programs, such as--
(A) the United States-Israel Binational Science
Foundation;
(B) the United States-Israel Binational Industrial
Research and Development Foundation; and
(C) the United States-Israel Energy Cooperation
Act.
(4) Those programs have made possible many scientific,
technological, and commercial breakthroughs in fields including
the life sciences, medicine, bioengineering, agriculture,
biotechnology, communications, and energy development.
(5) Israeli scientists are at the forefront of research and
development in the field of Alzheimer's disease.
(6) Enhanced cooperation between the United States and
Israel for the purpose of research in Alzheimer's disease would
be in the national interests of both countries.
SEC. 3. GRANTS FOR ALZHEIMER'S DISEASE RESEARCH.
(a) Grant Program.--
(1) Establishment.--The Secretary of Health and Human
Services (in this section referred to as the ``Secretary'')
shall establish a program of awarding grants to support
research on the development and commercialization of applicable
tools, treatments, and cures for Alzheimer's disease and other
dementias.
(2) Eligible projects.--To be eligible for funding under
this section, a project shall--
(A) be designed to further research described in
paragraph (1); and
(B) be a joint venture between--
(i)(I) a for-profit business entity,
academic institution, National Laboratory (as
defined in section 2 of the Energy Policy Act
of 2005 (42 U.S.C. 15801)), or nonprofit entity
in the United States; and
(II) a for-profit business entity, academic
institution, or nonprofit entity in Israel; or
(ii)(I) the Federal Government; and
(II) the Government of Israel.
(3) Applications.--To seek a grant under this section, an
applicant shall submit to the Secretary an application in
accordance with procedures established by the Secretary, in
consultation with the advisory board established under
paragraph (4).
(4) Advisory board.--
(A) Establishment.--The Secretary shall establish
an advisory board--
(i) to monitor the method by which grants
are awarded under this section; and
(ii) to provide to the Secretary periodic
performance reviews of actions taken to carry
out this section.
(B) Composition.--The advisory board established
under subparagraph (A) shall be composed of 3 members,
to be appointed by the Secretary, of whom--
(i) 1 shall be a representative of the
Federal Government;
(ii) 1 shall be selected from a list of
nominees provided by the United States-Israel
Binational Science Foundation; and
(iii) 1 shall be selected from a list of
nominees provided by the United States-Israel
Binational Industrial Research and Development
Foundation.
(5) Contributed funds.--Notwithstanding section 3302 of
title 31, United States Code, the Secretary may accept, retain,
and use funds contributed by any person, government entity, or
organization for purposes of carrying out this section--
(A) without further appropriation; and
(B) without fiscal year limitation.
(6) Report.--Not later than 180 days after the date of
completion of a project for which a grant is provided under
this section, the grant recipient shall submit to the Secretary
a report that contains--
(A) a description of the method by which the
recipient used the grant funds; and
(B) an evaluation of the level of success of each
project funded by the grant.
(7) Classification.--Grants shall be awarded under this
section only for projects that are considered to be
unclassified by both the United States and Israel.
(b) Termination.--The grant program and the advisory committee
established under this section terminate on the date that is 7 years
after the date of enactment of this Act.
(c) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section $3,000,000 for the period of
fiscal years 2015 through 2021. Any amounts appropriated pursuant to
this subsection shall be in addition to amounts accepted, retained, and
used pursuant to subsection (a)(5).
<all>
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line